Cara Bortz, PSYD Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 500 N Washington Ave Ste 105, Titusville, FL 32796 Phone: 321-268-0267 Fax: 321-268-3357 |
Dr. Richard D. Herman, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 6700 S. Us Hwy. 1, Titusville, FL 32780 Phone: 321-890-1500 |
Mrs. Holly Beth Bell, MS, BCBA Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 2073 Garden St, Titusville, FL 32796 Phone: 321-888-3020 |
Dr. Dayana Gonzalez, PSYD Psychologist Medicare: Medicare Enrolled Practice Location: 1537 N Singleton Ave, Titusville, FL 32796 Phone: 321-241-6800 Fax: 321-241-6890 |
Dr. Thomas F Guidera, PH.D. Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 1777 Garden St, Titusville, FL 32796 Phone: 321-268-5682 Fax: 321-268-5683 |
News Archive
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported additional clinical results for its lead product candidate, the Sufentanil NanoTab PCA System for the treatment of moderate-to-severe acute pain in the hospital setting.
HIV-infected adults currently are being recruited to participate in a clinical trial of 2009 H1N1 influenza vaccine. The study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, will enroll approximately 240 men and women between the ages of 18 and 64.
China Nuokang Bio-Pharmaceutical Inc., a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company has received the manufacturing license from the State Food and Drug Administration ("SFDA") for Dipyridamole Aspirin, a stroke-prevention product developed in-house.
Paediatric brain tumours preserve specific characteristics of the normal cells from which they originate - a previously unknown circumstance with ramifications for how tumour cells respond to treatment.
Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.
› Verified 9 days ago